1. New Zealand Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Zoono Group Limited

Zoono Group Limited

AASX:ZNO
0.05
AUD
+0.01
(+11.11%)
-0.04EPS
9.18MMarket Cap
Feb 25Next Earn
Zoono Group Limited
ASX:ZNO
(Australian Securities Exchange)

Recent

price

0.05

P/E

ratio

- -

div

yld

- -

ROIC.AI

2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
AUD
- -
- -
- -
- -
- -
- -
- -
- -
0.02
0.01
0.01
0.17
0.12
0.04
0.01
- -
Revenue per Share
-1.09
1.44
-0.66
-3.41
-1.49
-0.65
-2.21
-0.03
-0.09
- -
-0.01
0.07
0.02
-0.05
- -
-0.04
Basic EPS, GAAP
-0.64
-0.61
-0.67
-0.71
-0.42
-0.28
-0.22
-0.08
-0.01
- -
- -
- -
- -
- -
- -
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
0.02
- -
- -
- -
Dividend per Share
6.7
8.23
6.25
4.06
2.65
2.05
-0.31
-0.03
0.05
0.03
0.02
0.09
0.09
0.05
0.04
0.02
Book Value per Share
6.7
8.23
6.25
4.06
2.65
2.05
-0.31
-0.03
0.05
0.03
0.02
0.09
0.07
0.05
0.04
0.02
Tangible Book Value per Share
1
1
1
1
2
2
2
8
44
216
216
217
217
219
222
219
Basic Weighted Avg Shares
- -
- -
- -
- -
- -
- -
- -
- -
1
2
2
36
25
8
3
1
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
- -
- -
- -
-298.64
-33.29
-137.87
53.48
21.01
-71.42
-175.56
-387.12
Operating Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Depreciation Expense
-1
1
-1
-4
-2
-1
-5
- -
-4
- -
-2
16
4
-10
- -
-8
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
18.38
21.44
- -
- -
- -
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
-515.22
3.28
-136.12
43.46
17.44
-126.4
-10.5
-866.12
Profit Margin (%)
- -
- -
- -
- -
- -
- -
-1
- -
6
6
4
19
19
14
11
7
Working Capital
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
1
2
1
1
1
LT Debt
7
8
6
5
5
4
-1
- -
6
6
4
20
20
9
10
6
Total Equity
- -
-9.36
- -
- -
- -
- -
- -
- -
- -
-12.6
- -
110.39
17.84
- -
- -
- -
Return on Invested Capital (%)
- -
19.25
- -
- -
- -
- -
- -
- -
- -
1.42
- -
125.77
21.37
- -
- -
- -
Return on Capital (%)
-15.17
19.25
-9.16
-69.26
-46.08
-27.45
- -
- -
- -
1.26
-49.07
133.78
22.42
-69.23
-3.2
-101.45
Return on Common Equity (%)

Capital Structure

AUD

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

AUD

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

AUD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-208.31%
70.09%
-38.49%
Free Cash Flow
- -
- -
- -
Net Income, GAAP
-38.42%
241.64%
2,483.28%
Sales/Revenue/Turnover
- -
355.99%
-68.68%
Total Cash Common Dividend
- -
- -
- -

Semi-annual Revenue

AUD

•

in mil. unless spec.

Year

H1
H2
FY
2022
- -
- -
8
2023
- -
- -
3
2024
- -
- -
1

Semi-annual Earnings Per Share

AUD

•

in mil. unless spec.

Year

H1
H2
FY
2022
- -
- -
-0.05
2023
- -
- -
- -
2024
- -
- -
-0.04

Semi-annual Dividends Per Share

AUD

•

in mil. unless spec.

Year

H1
H2
FY
2022
- -
- -
- -
2023
- -
- -
- -
2024
- -
- -
- -
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Zoono Group Limited, along with its subsidiaries, operates as a global biotechnology firm specializing in the research, development, and distribution of advanced antimicrobial solutions across numerous international markets. The company's innovative product line, built around its proprietary ZOONO molecule, features sprays, wipes, and foams for hand and surface sanitization, as well as mold remediation, effectively bonding to surfaces for enduring protection against bacteria, viruses, fungi, and mold. Serving a broad range of sectors including aviation, healthcare, childcare, facilities management, transportation, education, and hospitality, Zoono is also actively advancing in fresh food shelf-life extension technology for packaging. This pioneering technology delivers scientifically validated, long-lasting, and non-toxic germ defense, with recent trials showing promising results and strategic expansions into Asian markets. Established in 2007, the company maintains its headquarters in Auckland, New Zealand, distributing its products throughout Australasia, Asia, the United States, the United Kingdom, and Europe.